CN111096979A - Safe and side-effect-free method for controlling blood sugar by applying stem cell therapy - Google Patents

Safe and side-effect-free method for controlling blood sugar by applying stem cell therapy Download PDF

Info

Publication number
CN111096979A
CN111096979A CN202010085961.2A CN202010085961A CN111096979A CN 111096979 A CN111096979 A CN 111096979A CN 202010085961 A CN202010085961 A CN 202010085961A CN 111096979 A CN111096979 A CN 111096979A
Authority
CN
China
Prior art keywords
stem cells
derived stem
autologous adipose
stem cell
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010085961.2A
Other languages
Chinese (zh)
Inventor
李军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Car T Shanghai Biotechnology Co ltd
Original Assignee
Car T Shanghai Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Car T Shanghai Biotechnology Co ltd filed Critical Car T Shanghai Biotechnology Co ltd
Priority to CN202010085961.2A priority Critical patent/CN111096979A/en
Publication of CN111096979A publication Critical patent/CN111096979A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention discloses a method for controlling blood sugar by applying stem cell therapy, which is safe and has no side effect, and the specific operation flow of the method is as follows: firstly, extracting autologous adipose-derived stem cells from a diabetic patient; conveying autologous adipose-derived stem cell tissues to a laboratory under the sterile and cold chain conditions, and separating to obtain initial autologous adipose-derived stem cells; culturing, amplifying and further purifying the initial autologous adipose-derived stem cells under a proper condition to obtain seed autologous adipose-derived stem cells, and freezing; finally, the expanded seed autologous adipose-derived stem cells are transfused to the diabetic patients in a hospital, the transfusing adopts an intravenous injection mode, and the average cell amount of the autologous adipose-derived stem cells injected each time is 10.26 multiplied by 107The preparation can be injected once every 7 to 28 days for 4 to 9 times in total, can effectively control blood sugar, brings new hope to diabetes patients, makes the diabetes reversal possible, promotes β cell regeneration, and can safely replace β cells of pancreatic islets with loss of function.

Description

Safe and side-effect-free method for controlling blood sugar by applying stem cell therapy
Technical Field
The invention belongs to the technical field of methods for controlling blood sugar, and particularly relates to a safe and side-effect-free method for controlling blood sugar by using a stem cell therapy.
Background
Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia caused by defective insulin secretion or impaired biological action or both of the two, i.e., hyperglycemia when the blood glucose level is higher than the normal range, which is also one of three generally known hyperglycemia, and hypertension and hyperlipidemia, respectively, fasting plasma glucose is lower than 6.1mmol/L, and blood glucose is lower than 7.8mmol/L at two hours after a meal, and if higher than this range, which is called hyperglycemia.
Three more or one less are the most common clinical manifestations of diabetes, i.e. polydipsia, polyphagia, polyuria and weight loss. The blood sugar is increased, the urine sugar is increased, and osmotic diuresis can be triggered, so that the symptom of diuresis is caused; blood sugar is increased, a large amount of water is lost, the blood osmotic pressure is correspondingly increased, and the hyperthrome can stimulate the thirst center of the hypothalamus, so that the symptoms of thirst and polydipsia are caused; due to the relative or absolute deficiency of insulin, glucose in the body cannot be utilized, and protein and fat consumption is increased, so that weakness and weight loss are caused; to compensate for lost sugar, maintain body movement, require more food intake; this forms the typical symptoms of more than three and less than three. The symptoms of polydipsia and polyuria of the diabetic are in direct proportion to the severity of the disease. In addition, it is noteworthy that the more a patient eats, the higher the blood sugar level, the more sugar is lost in urine, the more hunger is, and finally, the vicious circle is caused.
However, there are currently some diabetics in the clinic because there are no typical three more or one less symptoms that can lead to a delay in diagnosis. Some type II diabetics do not have obvious more than three or less symptoms, on one hand, because many diabetics find that the blood sugar is only slightly increased through physical examination, the blood sugar does not exceed or only slightly exceeds the renal sugar threshold, the renal sugar exclusion is very little, and the obvious more than three or less symptoms are not caused enough. On the other hand, due to the fact that the renal sugar threshold of some patients is increased, glucose is normally and completely reabsorbed in the kidney, and no sugar is discharged from urine; if the blood sugar is slightly increased, the reabsorption value of the renal tubules is correspondingly increased; however, when blood glucose rises to a level beyond the maximum reabsorption range of the renal tubules, some of the glucose will be excreted from the urine, resulting in diabetes. The critical value of the blood sugar is the renal threshold, and the normal value is 8.8-9.9 mmol/L. Kidney disease and other urinary system diseases can affect the disease to different degrees, and the renal threshold of most old patients is increased correspondingly. After the threshold of renal glucose is increased, the patient will not have diabetes even if the blood sugar is very high. Without diabetes, osmotic diuresis is not induced, and therefore, polyuria symptoms may not be present; without losing a large amount of water, the plasma osmotic pressure changes slightly, and the stimulation to the hypothalamic center is also reduced correspondingly, so that the symptoms of thirst and polydipsia can be avoided; without diabetes, a large amount of sugar is not lost, so that no obvious hunger sensation exists, and the polyphagia symptom is relieved; without diabetes, the loss of nutrients from the body is reduced and thus the degree of weight loss can be reduced accordingly. Thus, these diabetic patients may not eventually develop more or less than three symptoms.
Short-time and disposable hyperglycemia has no serious damage to human bodies, such as transient hyperglycemia in a stress state or in emotional agitation and high stress; a large amount of sugar is taken at a time, and transient hyperglycemia can also occur; subsequently, the blood glucose level gradually returns to normal. However, long-term hyperglycemia causes pathological changes of various tissues and organs of the whole body, and leads to the occurrence of acute and chronic complications, such as dehydration, electrolyte disorder, nutrient deficiency, resistance reduction, renal dysfunction, neuropathy, fundus oculi lesion, cardiovascular and cerebrovascular diseases, diabetic foot and the like, so that the control of hyperglycemia is imperative. The World Health Organization (WHO) issues warnings that about 1.1 million diabetics account for 1/10 of the total number of adults in china, and if actions are not taken as soon as possible, the number is predicted to increase to 1.5 million people in 2040 years due to reduction of risk factors in life styles such as unhealthy diet and lack of exercise. Non-infectious diseases such as diabetes and the like are the primary health threats in China, and nearly 100 million people die each year due to diabetes and diabetic complications; of these, nearly 40% of deaths are premature deaths, i.e., deaths in people under the age of 70.
Diabetes is generally diagnosed without difficulty by having a fasting blood glucose of greater than or equal to 7.0 mmole/l and/or a two hour postprandial blood glucose of greater than or equal to 11.1 mmole/l. Typing is performed after the diagnosis of diabetes. Type 1 diabetes mellitus: the disease is mild in age, mostly less than 30 years old, sudden onset, obvious symptoms of polydipsia, diuresis, polyphagia and emaciation, high blood sugar level, low levels of serum insulin and C-peptide and positive ICA, IAA or GAD antibodies, wherein a patient has ketoacidosis as a first symptom. The oral drug alone is ineffective and requires insulin therapy. Type 2 diabetes: it is common in middle-aged and elderly people, and is highly susceptible to obesity, hypertension, dyslipidemia, arteriosclerosis, etc. The early stage of the disease is unconscious without any symptom, or only the patients with mild hypodynamia, thirst and unobvious blood sugar increase can be diagnosed by a sugar tolerance test, and the serum insulin level is normal or increased in the early stage and is low in the late stage.
Diabetes is irreversible, and the goal of diabetes treatment is to delay the progression of diabetes as much as possible, because β cells in a human body gradually die once diabetes is acquired, which directly causes the course of diabetes to be irreversible.
Disclosure of Invention
The invention provides a safe and side-effect-free method for controlling blood sugar by using stem cell therapy, aiming at overcoming the defects in the prior art.
The invention is realized by the following technical scheme: a method for controlling blood sugar by stem cell therapy with safety and no side effect comprises the following specific operation procedures: firstly, extracting autologous adipose-derived stem cells from a diabetic patient; conveying autologous adipose-derived stem cell tissues to a laboratory under the sterile and cold chain conditions, and separating to obtain initial autologous adipose-derived stem cells; culturing the initial autologous adipose-derived stem cells under a proper condition, amplifying by ten thousand times, further purifying to obtain seed autologous adipose-derived stem cells, and freezing; finally, the expanded seed autologous adipose-derived stem cells are transfused to the diabetic patients in a hospital, the transfusing adopts an intravenous injection mode, and the average cell amount of the autologous adipose-derived stem cells injected each time is 10.26 multiplied by 107The injection is performed once every 7 to 28 days, and the total injection is performed for 4 to 9 times.
The GMP laboratory is a biological laboratory which meets the international cell preparation quality management system standard, and can provide the technical applications of separation and purification, culture and amplification, collection and cryopreservation, detection and quality control, cell recovery, product transportation, cell return and the like of stem cells for meeting the requirements of patients on treating diseases.
Cells are the basic structural and functional units of an organism, the human body is an organism consisting of about 40 trillion cells of 220 different tissues, and all life activities are completed by the cells. Stem cells are a kind of cells which are not fully differentiated and have potential functions of regenerating various tissues and organs, the stem cells are mainly used for repairing the tissues and organs and regulating immunity in vivo, the stem cells are primitive cells with self-renewal, replication and multidirectional differentiation potential, embryonic stem cells are totipotent stem cells, all the cells originate from one stem cell, and adult stem cells are multifunctional or monofunctional stem cells. The stem cells are classified into totipotent stem cells, multifunctional stem cells and monofunctional stem cells according to functions, wherein the totipotent stem cells are embryonic stem cells, the multifunctional stem cells comprise mesenchymal stem cells and hematopoietic stem cells, and the monofunctional stem cells comprise neural stem cells, liver stem cells, skin stem cells and muscle stem cells.
Cell therapy (cell therapy) refers to a treatment mode in which certain cells with specific functions are obtained by a bioengineering method and/or are treated by in vitro amplification, special culture and the like, and then are transfused back to a patient. The safe and non-side-effect method for controlling blood sugar by using stem cell therapy belongs to a cell therapy method. The action mechanism of the stem cells as the therapeutic drugs is as follows: after entering a human body, the stem cells are gathered at the injured or diseased part through the homing effect, and then are immunoregulated and cytotrophized by secreting bioactive factors, and finally, the stem cells are activated to repair tissues.
The invention has the advantages that the stem cell therapy can effectively control blood sugar and bring new hope to diabetics, the technical scheme of the invention makes it possible to reverse diabetes, can promote the regeneration of β cells and can safely replace insulin β cells with lost functions, the invention can well control blood sugar, can reduce the dosage of insulin and really improve the life quality of the diabetics, and the technical scheme of the invention can achieve real safe no side effect and can quickly improve related complications caused by the diabetes.
Drawings
FIG. 1 is a graph comparing fasting plasma glucose with a control group using the method for controlling plasma glucose of the present invention;
FIG. 2 is a graph comparing HbA1c with a control group using the method of controlling blood glucose in accordance with the present invention.
Detailed Description
The present invention will be described in detail with reference to specific embodiments.
A method for controlling blood sugar by stem cell therapy with safety and no side effect comprises the following specific operation procedures: firstly, extracting autologous adipose-derived stem cells from a diabetic patient; the autologous adipose-derived stem cell tissue is transported to the parenchyma under the aseptic and cold chain conditionsLaboratory testing, and separating to obtain initial autologous adipose-derived stem cells; culturing the initial autologous adipose-derived stem cells under a proper condition, amplifying by ten thousand times, further purifying to obtain seed autologous adipose-derived stem cells, and freezing; finally, the expanded seed autologous adipose-derived stem cells are transfused to the diabetic patients in a hospital, the transfusing adopts an intravenous injection mode, and the average cell amount of the autologous adipose-derived stem cells injected each time is 10.26 multiplied by 107The injection is performed once every 7 to 28 days, and the total injection is performed for 4 to 9 times. The GMP laboratory is a biological laboratory which meets the international cell preparation quality management system standard, and can provide separation and purification, culture and amplification, collection and cryopreservation, detection quality control, cell recovery, product transportation and cell return transfusion of stem cells for meeting the requirements of patients on treating diseases.
As shown in fig. 1 to 2, fig. 1 is a graph comparing fasting plasma glucose with a control group using the method for controlling plasma glucose of the present invention, and fig. 2 is a graph comparing HbA1c with a control group using the method for controlling plasma glucose of the present invention. As can be seen from the graphs in fig. 1 to 2, the stem cell therapy of the present invention can control blood glucose well, and it is found through multiple clinical experiments and long-term studies that the stem cell therapy can significantly reduce fasting blood glucose FPG and HbA1c of diabetic patients.
Finally, it should be noted that the above-mentioned contents are only used for illustrating the technical solutions of the present invention, and not for limiting the protection scope of the present invention, and that the simple modifications or equivalent substitutions of the technical solutions of the present invention by those of ordinary skill in the art can be made without departing from the spirit and scope of the technical solutions of the present invention.

Claims (2)

1. A safe and side-effect-free method for controlling blood glucose by using stem cell therapy, which is characterized in that: the specific operation flow of the method for controlling the blood sugar by applying the stem cell therapy, which is safe and has no side effect, is as follows: firstly, extracting autologous adipose-derived stem cells from a diabetic patient; conveying autologous adipose-derived stem cell tissues to a laboratory under the sterile and cold chain conditions, and separating to obtain initial autologous adipose-derived stem cells; starting autologous adipose-derived stem cells in a suitable stripCulturing under a condition, amplifying by ten thousand times, further purifying to obtain seed autologous adipose-derived stem cells, and freezing; finally, the expanded seed autologous adipose-derived stem cells are transfused to the diabetic patients in a hospital, the transfusing adopts an intravenous injection mode, and the average cell amount of the autologous adipose-derived stem cells injected each time is 10.26 multiplied by 107The injection is performed once every 7 to 28 days, and the total injection is performed for 4 to 9 times.
2. The method for controlling blood glucose using stem cell therapy according to claim 1, which is safe and free of adverse effects, comprising: the laboratory adopts the GMP laboratory, and the GMP laboratory adopts the biological laboratory who accords with international cell preparation quality control system standard, and the GMP laboratory can provide separation and purification, culture amplification, collection cryopreserving, detection quality control, cell recovery, product transportation and the cell feedback of stem cell for satisfying the demand of patient's treatment disease.
CN202010085961.2A 2020-02-11 2020-02-11 Safe and side-effect-free method for controlling blood sugar by applying stem cell therapy Pending CN111096979A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010085961.2A CN111096979A (en) 2020-02-11 2020-02-11 Safe and side-effect-free method for controlling blood sugar by applying stem cell therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010085961.2A CN111096979A (en) 2020-02-11 2020-02-11 Safe and side-effect-free method for controlling blood sugar by applying stem cell therapy

Publications (1)

Publication Number Publication Date
CN111096979A true CN111096979A (en) 2020-05-05

Family

ID=70427957

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010085961.2A Pending CN111096979A (en) 2020-02-11 2020-02-11 Safe and side-effect-free method for controlling blood sugar by applying stem cell therapy

Country Status (1)

Country Link
CN (1) CN111096979A (en)

Similar Documents

Publication Publication Date Title
CN1310668C (en) Medicine for treating diabetes, and its prepn. method
Balwan et al. Burden of diabetes and role of medicinal plants in its treatment
CA3022247C (en) Composition for treating diabetic disease
CN111281884A (en) Method for reducing insulin dosage of diabetic patient by using stem cell therapy
CN111096979A (en) Safe and side-effect-free method for controlling blood sugar by applying stem cell therapy
CN102078397B (en) Traditional Chinese medicine compound and preparation method thereof
CN103055176B (en) Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof
CN101433329A (en) Nutritive composition with health-care function
CN105031619A (en) Application of secretion factor GREM2 in preparation of medicament for treating type 2 diabetes
CN102191207A (en) Gene engineering bacterium of expression of soluble FGF-21 and construction method and application thereof
CN106474455A (en) A kind of application in preparing anti-type ii diabetes medicine or health product for Folium Camelliae sinensis polypeptide
CN111035656A (en) Method for improving life quality of diabetic by using stem cell therapy
CN111281885A (en) Method for reversing liver fibrosis by applying stem cell therapy
CN104784192A (en) Application of clam meat oligosaccharide in preparation of hypoglycemic drugs and preparation method of clam meat oligosaccharide
CN110302213A (en) Maggot is for treating the application in diabetes
CN110327373A (en) Maggot infusing drugs in wine product is for treating the application in diabetes
CN111214641A (en) Traditional Chinese medicine preparation for treating diabetes
Mbagwu et al. Hypoglycemic activity of ethanol leaf extract of Grona trifloral in alloxan induced diabetic mice
CN118267401B (en) Tremella pedicel head polysaccharide faeces fungus and application thereof in colonitis
CN1121869C (en) Sugar-correcting capsule
Shelke et al. Recent Trends in the Therapeutic Approach of Type 2 Diabetes Mellitus
CN112535282A (en) Food for regulating diabetes
Rafikovna Modern concepts of insulin-like growth factors in normal conditions and their role in diabetes mellitus
CN109010368B (en) Cell preparation for treating triple sign of female athletes and repairing female athlete ovary function and preparation method thereof
EA035673B1 (en) Mixture for treating pathologies associated with lymphatic hyperpermeability

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200505

WD01 Invention patent application deemed withdrawn after publication